This is a news story, published by Investor's Business Daily, that relates primarily to Bristol Myers Squibb news.
For more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
Bristol Myers Squibb stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest earnings news, stock news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Bristol Myers SquibbInvestor's Business Daily
•82% Informative
Bristol Myers Squibb ( BMY ) reported adjusted earnings of $ 2.07 per share on $12.2 billion in second-quarter sales.
Blood thinner Eliquis buoyed revenue while cost cutting efforts also helped the bottom line.
For the year , the company guided to earnings of 60-90 cents from 40-70 cents previously.
VR Score
84
Informative language
85
Neutral language
30
Article tone
formal
Language
English
Language complexity
29
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
3
Affiliate links
no affiliate links